A New Approach to Hair Loss Grounded in Stem Cell Biology

We target the hair follicle directly to stimulate growth

Innovative Science

Based on UCLA scientists' groundbreaking discovery that hair follicle stem cells have a unique metabolic switch, Pelage's platform is the first to target this novel mechanism to activate stem cells and regrow hair.

For Everyone

By targeting the intrinsic metabolic properties of hair follicle stem cells, Pelage's treatment has potential to induce robust hair growth for all genders, skin types, and hair types.


The small molecule drug platform stimulates hair growth without the need for invasive procedures or oral systemic exposure.

Our Mission

At Pelage, our goal is to deliver a clinically-tested treatment grounded in innovative science for all genders, skin types, and hair types. Based on breakthrough discoveries by Pelage co-founders, we activate hair growth through a first-in-class mechanism that targets the metabolism of hair follicle stem cells.​

Types of Hair Loss

Current Hair Loss
Treatments Are Inadequate

Existing therapies target external factors affecting hair growth (e.g. anti-androgen drugs like finasteride Propecia)

Current treatments have limited efficacy and unclear mechanism of action (e.g. minoxidil Rogaine and platelet-rich plasma PRP). Most are not FDA-approved.

Treatment options are not suitable for all patients and can be invasive or require oral dosing (e.g. spironolactone, hair transplantation)

The Pelage Solution

A novel, non-invasive, topical small molecule drug platform that activates stem cells in the hair follicles directly to stimulate robust hair growth. By targeting an intrinsic metabolic switch in hair follicles, Pelage’s platform is suitable for all genders, skin types, and hair types.

How Our Drug Works

Hair follicle stem cells (HFSCs) undergo cycles of dormancy and activation to power hair growth.

In alopecia related to age, stress, hormones, and chemotherapy, hair follicle stem cells can become "stuck" in the dormant phase and unable to trigger hair growth. However, these stem cells are still present and viable in the follicles.

Our drug activates dormant hair follicle stem cells, restoring the regenerative capacity of the follicle and triggering new hair growth.



  • Pioneers novel approach to restore the body’s natural ability to grow hair by reactivating dormant hair follicle stem cells
  • Phase I clinical data meets primary safety endpoints and shows statistically significant stem cell activation in hair follicles after one week of treatment with PP405; Phase 2 clinical trial to begin in mid-2024
  • Announces the appointment of Qing Yu Christina Weng, M.D., as Chief Medical Officer
  • Potent topical MPC inhibitor, based on discovery of a metabolic switch, reawakens dormant hair follicle stem cells to stimulate hair growth
  • PP405 demonstrates statistically significant activation of Ki67 in the hair follicle, a well-established marker of stem cell proliferation


GV Logo
Visionary Ventures Logo White
YK Bioventures Logo
Main Street Advisors Logo


William Lowry, PhD

President & Co-Founder

President & Co-Founder
Professor, UCLA Molecular, Cell and Dev. Biology 

Dr. Lowry is a leader in the stem cell field with 20+ years of research experience resulting in the discovery that hair follicle stem cells can be activated by metabolic manipulation. His work has led to the creation of several startups including Pelage and Sardona, as well as other efforts under development.


Heather Christofk , PhD


Professor, UCLA Biological Chemistry

Dr. Christofk is a leader in the metabolism field with a research focus on how metabolism regulates cell state transitions. Her groundbreaking collaborative research with Dr. Lowry revealed that changes in metabolism can instruct hair follicle stem cell activation, forming the basis for the Pelage’s approach to treat hair loss. She is a Professor of Biological Chemistry at the David Geffen School of Medicine at UCLA and Associate Director of Basic and Translational Research at the UCLA Jonsson Comprehensive Cancer Center. She earned her bachelor’s degree from UCLA, her PhD from Harvard, and conducted postdoctoral research at UCSF before joining the faculty at UCLA in 2008.


Michael Jung, PHD


Professor, UCLA Chemistry & Biochemistry

Dr. Jung is a renowned Medicinal Chemist and co-founder of several successful startups. He is also co-inventor of two FDA approved drugs for prostate cancer (Xtandi & Erleada) with several drugs currently in clinical trials.


Daniel Gil, PhD

Chief Executive Officer

Chief Executive Officer

Dr. Gil is the CEO of Pelage. He is also a Venture Partner with Visionary Ventures. Until 2018, Dr. Gil was a Vice President at Allergan, overseeing the research portfolio and early clinical development. His research contributed to development of 5 marketed drugs and he led 8 clinical development projects. He is an inventor on 70+ issued US patents and author on 45 peer-reviewed research articles. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from the University of Pennsylvania.


Qing Yu Christina Weng, MD

Chief Medical Officer

Chief Medical Officer

Dr. Weng is the CMO of Pelage. She is a physician-scientist and entrepreneur, board-certified dermatologist, and Lecturer at Harvard Medical School. She is experienced in corporate startup strategy as Head of Business Development & Strategy at Kira Pharma and CSO and cofounder of Mymiel Skincare. She is on the Board of Directors for the Dermatology Innovation Forum and Dermatology Summit. Dr. Weng has an undergraduate degree from the California Institute of Technology, MD from Harvard, and she completed dermatology residency and fellowship at Harvard.